Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause Channelopathies

A composition for preventing or treating a diseases with an active agent or drug that causes one or more adverse reactions arising from administration of an active agent or drug in a human that causes at least one of cardiac channelopathies, IKr channel inhibition or QT prolongation comprising:

• an amount of a lysophosphatidylglycerol with a basic structure:
• wherein R1 or R2 can be any even or odd-chain fatty acid, and R3 can be H, acyl, alkyl, aryl, amino acid, alkenes, alkynes, adapted for oral administration effective to reduce or prevent the at least one cardiac channelopathies, IKr channel inhibition or QT prolongation caused by the drug;
• one or more active agents or drugs that causes at least one of IKr channel inhibition or QT prolongation;
• and
• one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.

A method for preventing or treating one or more cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation, in a human or animal subject caused by an active agent or drug, wherein the active agent or drug are used to treat a disease in a human or animal subject comprising the steps of:

• administering to the human or animal subject an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition, or QT prolongation caused by the active agent or drug;
• an effective amount of the active agent or drug sufficient to treat the disease, wherein the orally provided lysophosphatidylglycerol reduces or eliminates the at least one cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation;
• and
• one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.